Therapies
Thursday, June 27th, 2013
Diabetes Care: July 1, 2013 OBJECTIVE Few tools are available to evaluate clinical outcomes and response to thrombolysis (tPA) in stroke patients with diabetes. We explored how the iScore (www.sorcan.ca/iscore), a validated risk score, predicts clinical outcomes in stroke patients with and without diabetes. RESEARCH DESIGN AND METHODS We applied the iScore to stroke patients presenting to stroke […]
Therapies
Thursday, June 27th, 2013
PLOS: 6/25/13 Patients with chronic disease may experience complicated management plans requiring significant personal investment. This has been termed ‘treatment burden’ and has been associated with unfavourable outcomes. The aim of this systematic review is to examine the qualitative literature on treatment burden in stroke from the patient perspective. Read more
Therapies
Thursday, June 27th, 2013
AHA: 5/23/13 The Stroke Acute Management With Urgent Risk-Factor Assessment and Improvement-Intracerebral Hemorrhage Study Background and Purpose—Blood pressure (BP) lowering is often conducted as part of general acute management in patients with acute intracerebral hemorrhage. However, the relationship between BP after antihypertensive therapy and clinical outcomes is not fully known. Methods—Hyperacute (<3 hours from […]
Therapies
Friday, June 21st, 2013
JAMA: June 19, 2013 Importance Randomized clinical trials suggest the benefit of intravenous tissue-type plasminogen activator (tPA) in acute ischemic stroke is time dependent. However, modest sample sizes have limited characterization of the extent to which onset to treatment (OTT) time influences outcome; and the generalizability of findings to clinical practice is uncertain. Objective To […]
Therapies
Friday, June 21st, 2013
STROKEAHA: June 18, 2013 Background and Purpose—Previous economic studies outside Australia have demonstrated that patients treated with tissue-type plasminogen activator (tPA) within 4.5 hours of stroke onset have lower healthcare costs than those not. We aim to perform cost-effectiveness analysis of intravenous tPA in an Australian setting. Methods—Data on clinical outcomes and costs were derived for […]
Therapies
Friday, June 21st, 2013
BMC Health Services Research: June 18, 2013 Background Tools to support clinical or patient decision-making in the treatment/management of a health condition are used in a range of clinical settings for numerous preference-sensitive healthcare decisions. Their impact in clinical practice is largely dependent on their quality across a range of domains. We critically analysed currently available […]
Therapies
Tuesday, June 18th, 2013
J NeuroIntervent Surgery: June 15, 2013 Background and purpose The optimal management of stroke patients who fail treatment with intravenous recombinant tissue plasminogen activator (rt-PA) remains unknown. A study was undertaken to establish whether treatment with a standard intravenous t-PA dose (0.9 mg/kg) followed by multimodal endovascular therapy would have a similar safety profile to reduced dose […]
Therapies
Tuesday, June 18th, 2013
PhRMA: June 14, 2013 Biopharmaceutical research companies are developing 215 medicines for two of the leading causes of death in Ameri- cans—heart disease and stroke. Medi- cines have helped cut deaths from these diseases by 30 percent between 2001 and 2011, and in 2008 stroke dropped to the fourth leading cause of death after being […]
Therapies
Tuesday, June 18th, 2013
STROKEAHA: June 11, 2013 Background and Purpose—Diffusion-weighted imaging (DWI) lesion volume is associated with poor outcome after thrombolysis, and it is unclear whether endovascular therapies are beneficial for large DWI lesion. Our aim was to assess the impact of pretreatment DWI lesion volume on outcomes after endovascular therapy, with a special emphasis on patients with complete […]
Therapies
Tuesday, June 18th, 2013
STROKEAHA: June 11, 2013 Background and Purpose—The purpose of this study was to analyze the 30-day outcome after introduction of a rapid carotid endarterectomy (CEA) program. Reasons for delay in CEA and the incidence of early recurrence neurological symptoms were recorded. Methods—This is a prospective population-based study of delays to CEA and 30-day outcome in patients […]
